MetaCap

Pulse Biosciences Inc (PLSE)

NASDAQ: PLSEHealth CareMedical/Dental InstrumentsUSD

45.55+1.14 (+2.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PLSE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.21
52-week range
12.95 – 58.94
Day range
43.84 – 46.00
Volume / Avg
466.80K / 503.52K
Beta
—

52-week range

$12.95$58.94

PLSE stock today

Pulse Biosciences (PLSE) closed at $45.55 on Nov 20, up 2.57% (+$1.14), versus the S&P 500's 3.70% decline. At this level, PLSE sits in the middle of its 52-week range of $12.95 to $58.94: 22.7% below the high, set on Nov 9, 2026 and 251.7% above the low. PLSE is up 231.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 250.1%.

Pulse Biosciences has posted a net loss over the last twelve months (EPS of -$1.21), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pulse Biosciences

Company profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.

Industry
Medical/Dental Instruments
CEO
Mr. Paul Arthur LaViolette M.B.A.
Headquarters
Miami, FL
Employees
116
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Pulse Biosciences generated $350,000 in revenue, up 0.0% from fiscal 2024. Pulse Biosciences reported a net loss of $72.8 million, compared with a loss of $53.6 million a year earlier. Gross margin was -54.0% and operating margin -21982.6%.

Pulse Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$350.00K$0$0$700.00K$1.42M
Growth——-100.00%-50.63%—
Net income$-72.78M$-53.59M$-42.21M$-58.51M$-63.66M
EPS (diluted)————$-2.28

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$67.67+48.56%

  • Strong buy 1
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $60.00High $74.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.29 vs $-0.35
Surprise
+17.14%

PLSE news

All PLSE news

Pulse Biosciences peers

Health Care sector
PLSE peer companies
CompanyPrice% ChgMarket capCompare
IRTCiRhythm Holdings Inc.94.72+0.51%$3.18Bvs PLSE
NVSTEnvista Holdings Corporation22.91-1.55%$3.67Bvs PLSE
ATRCAtriCure Inc.55.39+2.37%$2.82Bvs PLSE
HTFLHeartflow Inc.46.69+4.62%$4.10Bvs PLSE
STVNStevanato Group S.p.A.15.65-1.76%$4.27Bvs PLSE
ICUIICU Medical Inc.172.52-1.84%$4.31Bvs PLSE
UFPTUFP Technologies Inc.290.85-2.70%$2.25Bvs PLSE
MMEDMiniMed Group Inc.16.01-1.54%$4.50Bvs PLSE

Indexes, lists and sector

Pulse Biosciences stock FAQ

What is Pulse Biosciences's stock price today?

PLSE last traded at $45.55 as of Nov 20, 4:00 PM EST, up 2.57% on the day. Prices are delayed at least 15 minutes.

Who is Pulse Biosciences's CEO?

Mr. Paul Arthur LaViolette M.B.A. is the chief executive officer of Pulse Biosciences Inc, which has about 116 employees.

What is the PLSE 52-week high?

The 52-week high for PLSE is $58.94 and the 52-week low is $12.95. The stock is currently 22.7% below its high.

Compare PLSE